[Doxazosin in the treatment of light-to-moderate arterial hypertension in a non-comparative multicenter study].

: This is an open non-comparative study to evaluate the efficacy and tolerability of doxazosin mesilate in 540 subjects with either history or newly diagnosed mild/moderate hypertension. In all adult subjects of both sexes enrolled in this study, the diastolic blood pressure (DBP) was in the range of 95-115 mmHg at two different measurements both in clino- and orthostatism, in the absence of any heart pathology. Those patients who, after one-week wash-out period, reported DPB > or = 95 mmHg, were given doxazosin as a single daily dose. The initial dosage was 1 mg for three days; afterwards, patients have been instructed to take a whole 2 mg tablet in the morning up to the following visit (i.e. 14 days after the first administration). In case or = 65 yrs. has not shown a significant difference. At week 24, a total of 540 subjects had completed the treatment. BP value normalization has been achieved with a mean dosage of 3.1 +/- 1.2 mg/day of doxazosin. Doxazosin administration did not produce clinically significant effects on heart rate. Laboratory data have evidenced a statistically significant increase in HDL cholesterol (p or = 65 yrs. (116 patients) only a delta/percentage variation of HDL cholesterol with respect to baseline has been evidenced, after 24 weeks of treatment.